Treatment protocol for B-cell mature non-Hodgkin's lymphoma in children and adolescents
Official title: B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021)
Run by Federal Research Institute of Pediatric Hematology, Oncology and Immunology · NCT05518383 · Data updated 2026-11-12
This study is testing different treatment plans for children and teenagers with B-cell non-Hodgkin's lymphoma to see who needs stronger therapy and who can safely have gentler options.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 1 Day to 18 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Federal Research Institute of Pediatric Hematology, Oncology and Immunology Academic / other |
| Drugs / interventions | rituximab, chemotherapy |
| Locations | 1 site (Moscow, RF) |
| Status | Recruiting |
| Started | May 25, 2022 |
| Main results expected | May 16, 2025 |
| Study ends | May 16, 2027 |
| Registry record updated | August 26, 2022 |
| Trial ID | NCT05518383 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include children and adolescents aged 0 to 18 years diagnosed with specific types of B-cell non-Hodgkin's lymphoma.
✕Probably not a fit
Patients with previous malignancies, organ transplants, or severe immunodeficiencies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial evaluates the molecular characteristics and minimal residual disease of B-cell non-Hodgkin's lymphoma (B-NHL) in pediatric patients. It aims to identify high-risk groups for more intensive treatment while determining which patients can safely receive less aggressive therapy. The study also assesses the role of PET/CT scans in evaluating remission completeness. Various treatment regimens involving rituximab and other chemotherapeutic agents are tested to optimize patient outcomes and reduce toxicity.
Why it matters
Potential benefit: If successful, this study could lead to more tailored and less toxic treatment options for children and adolescents with B-cell mature non-Hodgkin's lymphoma.
How similar studies have gone: Other studies have shown promise in using rituximab for similar conditions, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age at diagnosis 0 to 18 years. * The diagnosis of Burkitt's lymphoma, Diffuse large B-cell lymphom, primary mediastinal lymphoma, primary CNS lymphoma, B-cell (Burkitt) AL * Informed consent of the patient parents (guardians) to be treated Exclusion Criteria: * previous malignancy, prior organ transplant, HIV infection or AIDS or severe immunodeficiency * hypersensitivity to rituximab or to ingredients of other IMPs. * no informed consent of the patient parents (guardians) to be treated
Where it's running
-
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology
Moscow, Rf, Russia Recruiting
Study contacts
- Study coordinator: Yulia Abugova
- Email: Yuliya.Abugova@fccho-moscow.ru
- Phone: +7-916-074-74-76
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310
This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.
-
Gene therapy for certain blood cancers
This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.
-
Zilovertamab Vedotin for Pediatric and Young Adult Cancer Patients
This study is testing a new drug called zilovertamab vedotin to see if it can help kids and young adults with certain types of cancer that haven't responded to other treatments.
-
Study of crushed venetoclax tablets dissolved in liquid for pediatric patients
This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.
-
Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies
This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.
-
Using modified T cells to treat relapsed or refractory Non-Hodgkin Lymphoma
This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.